cbdMD, Inc. (YCBD)
| Market Cap | 5.60M -9.6% |
| Revenue (ttm) | 20.93M +10.0% |
| Net Income | -3.08M |
| EPS | -0.32 |
| Shares Out | 11.21M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 153,458 |
| Open | 0.5139 |
| Previous Close | 0.4971 |
| Day's Range | 0.4800 - 0.5139 |
| 52-Week Range | 0.4650 - 2.5600 |
| Beta | 2.17 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 13, 2026 |
About YCBD
cbdMD, Inc. produces and distributes various cannabidiol (CBD) products in the United States and internationally. The company owns and operates various consumer hemp-based CBD brands. Its cbdMD brand products include oils, gummies, capsules, soft-gels, topicals, functional formulations, and hemp-derived compliant Delta-9 THC products. It also provides products for dogs and cats, including tinctures, chews, and topicals under the Paw CBD brand name; non-cannabinoid functional ingredients, such as functional mushrooms under the ATRx brand; and he... [Read more]
Financial Performance
In fiscal year 2025, cbdMD's revenue was $19.19 million, a decrease of -1.50% compared to the previous year's $19.48 million. Losses were -$4.38 million, -43.21% less than in 2024.
Financial StatementsNews
cbdMD downgraded to Hold from Buy at Maxim
Maxim downgraded cbdMD (YCBD) to Hold from Buy.
cbdMD Earnings Call Transcript: Q3 2026
Revenue grew 20% year-over-year to $5.6M, led by wholesale and new product launches, while gross margin declined due to regulatory costs. Cost reduction initiatives are underway, with break-even revenue now modeled in the low to mid $6M range. Regulatory uncertainty remains a key risk.
cbdMD Quarterly report: Q3 2026
cbdMD has published its Q3 2026 quarterly earnings report on August 13, 2026.
cbdMD Earnings release: Q3 2026
cbdMD released its Q3 2026 earnings on August 13, 2026, summarizing the period's financial results.
cbdMD Reports 20% Year-over-Year Revenue Growth for the Third Fiscal Quarter of 2026
Accelerating Oasis Beverage Momentum, a Full Quarter of Bluebird Botanical Contribution, and Advancing Federal Hemp Legislation Strengthen the Company's Positioning for Competing under Pending Federal...
cbdMD, Inc. to Host Conference Call to Discuss June 30, 2026, Third Quarter Results
CHARLOTTE, N.C., Aug. 10, 2026 /PRNewswire/ -- cbdMD, Inc. (NYSE American: YCBD), one of the nation's leading, highly trusted and widely recognized CBD companies, today announces that it will host a c...
cbdMD Applauds Proposed SENATE SPENDING BILL That Would Protect Access to Full-Spectrum CBD and Other Naturally Derived Hemp Products
Senate continuing resolution text released August 2 would delay the pending November federal hemp restrictions. CHARLOTTE, N.C.
cbdMD Supports the Bipartisan Lawful Hemp Protection Act to Protect Consumers and Full-Spectrum CBD Access
Company backs the Barr-Craig framework and the administration's call to fix the federal hemp definition before the November deadline CHARLOTTE, N.C., July 24, 2026 /PRNewswire/ -- cbdMD, Inc. (NYSE Am...
cbdMD’s Oasis brand partners with Mexcor to launch into South Carolina
cbdMD’s (YCBD) Oasis line of hemp-derived beverages is now available in South Carolina through a new distribution agreement with Morales Beverage Group, South Carolina, a beverage statewide alcohol di...
cbdMD's Oasis Brand Partners with Mexcor to Launch Into South Carolina
Hemp-derived THC beverages, including the new zero-proof Mixer, roll out to liquor retailers statewide CHARLOTTE, N.C., July 14, 2026 /PRNewswire/ -- cbdMD, Inc. (NYSE American: YCBD) today announced ...
cbdMD’s Bluebird Botanicals announces official partnership with Denver Audubon
cbdMD (YCBD) through its Bluebird Botanicals brand announced an official partnership with Denver Audubon, a Colorado-based conservation organization. “Bluebird has always stood for more than products,...
cbdMD's Bluebird Botanicals Announces Official Partnership With Denver Audubon to Support Bird Conservation
Partnership reinforces Bluebird Botanicals' Colorado roots, environmental values, and commitment to responsible growth under cbdMD leadership CHARLOTTE, N.C., July 9, 2026 /PRNewswire/ -- cbdMD, Inc. ...
cbdMD completes self-affirmed GRAS determination supporting CBD consumption
cbdMD (YCBD) announced the completion of a self-affirmed Generally Recognized as Safe, GRAS, determination supporting the safe consumption of up to 200 mg per day of cannabidiol, CBD, as delivered…
cbdMD Sets a New Safety Standard for Broad Spectrum CBD With Self-Affirmed GRAS Determination
Years of peer-reviewed safety research position cbdMD's broad spectrum CBD for a new era of evidence-based, clinically supported wellness. CHARLOTTE, N.C.
Oasis Launches Hemp-Derived Mixer
A quadruple-filtered, zero-proof spirit with a resealable, child-resistant cap; ready to enjoy on its own or built into a mocktail CHARLOTTE, N.C., July 1, 2026 /PRNewswire/ -- cbdMD, Inc. (NYSE Ameri...
cbdMD Welcomes White House Call for Fair Treatment of Hemp-Derived Products
As federal reclassification efforts advance and major U.S. exchanges open to compliant operators, cbdMD points to its position as an established, NYSE American–listed company in a maturing cannabinoid...
cbdMD appoints Wade Brown as Chief Marketing Officer
cbdMD (YCBD) announced the appointment of Wade Brown as Chief Marketing Officer. “Brown joined cbdMD in March 2025 and has been central to stabilizing the Company’s brand portfolio and supporting…
cbdMD Appoints Wade Brown Chief Marketing Officer
Veteran consumer-wellness growth operator to lead multi-brand expansion across DTC, Amazon, retail, and new categories CHARLOTTE, N.C., June 16, 2026 /PRNewswire/ -- cbdMD, Inc. (NYSE American: YCBD),...
cbdMD Earnings Call Transcript: Q2 2026
Net sales rose 19% year-over-year to $5.6 million, driven by core growth and the Bluebird Botanicals acquisition. Gross margin declined to 58% due to wholesale mix and compliance costs, while strategic investments in Medicare and regulatory agility position the company for long-term growth.
cbdMD Quarterly report: Q2 2026
cbdMD has published its Q2 2026 quarterly earnings report on May 14, 2026.
cbdMD Earnings release: Q2 2026
cbdMD released its Q2 2026 earnings on May 14, 2026, summarizing the period's financial results.
cbdMD Reports 19% Year-over-Year and 12% Sequential Revenue Growth; Bluebird Acquisition Integration and Medicare BEI Pathway Position Company for Continued Momentum
CHARLOTTE, N.C. , May 14, 2026 /PRNewswire/ -- cbdMD, Inc. (NYSE American: YCBD), one of the nation's leading and most trusted CBD companies and operator of the cbdMD, Bluebird Botanicals, and Paw CBD...
cbdMD, Inc. to Host Conference Call to Discuss March 31, 2026, Second Quarter Results
CHARLOTTE, N.C., May 12, 2026 /PRNewswire/ -- cbdMD, Inc. (NYSE American: YCBD), one of the nation's leading, highly trusted and widely recognized CBD companies, today announces that it will host a co...
cbdMD Launches Clinical Healthcare Channel to Support First Federal Pathway for Hemp-Derived CBD in Medicare
Company brings one of the only combined clinical and toxicological safety dataset in the hemp-derived CBD category into a new provider channel as CMS activates cannabinoid access within value-based ca...
cbdMD Transcript: AGM 2026
The meeting covered director elections, auditor ratification, a reverse stock split, preferred stock conversions, an equity line of credit, and an equity compensation plan, all of which were approved by shareholders. A business update is planned for May.